A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate

NCT00740051 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

227

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Linagliptin
DRUG: Linagliptin Placebo
DRUG: Glimepiride

Sponsor

Boehringer Ingelheim